186 related articles for article (PubMed ID: 29467478)
1. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.
Moktefi A; Pouessel D; Liu J; Sirab N; Maille P; Soyeux P; Bergman CC; Auriault ML; Vordos D; Taille A; Culine S; Allory Y
Mod Pathol; 2018 Aug; 31(8):1270-1281. PubMed ID: 29467478
[TBL] [Abstract][Full Text] [Related]
2. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
[TBL] [Abstract][Full Text] [Related]
3. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
[TBL] [Abstract][Full Text] [Related]
4. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
5. HER2 Immunohistochemistry in Invasive Micropapillary Breast Carcinoma: Complete Assessment of an Incomplete Pattern.
Perron M; Wen HY; Hanna MG; Brogi E; Ross DS
Arch Pathol Lab Med; 2021 Aug; 145(8):979-987. PubMed ID: 33212478
[TBL] [Abstract][Full Text] [Related]
6. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features.
Stewart RL; Caron JE; Gulbahce EH; Factor RE; Geiersbach KB; Downs-Kelly E
Mod Pathol; 2017 Nov; 30(11):1561-1566. PubMed ID: 28752841
[TBL] [Abstract][Full Text] [Related]
7. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
[TBL] [Abstract][Full Text] [Related]
8. Reappraisal of HER2 Amplification in High-Grade Urothelial Carcinoma Based on 2018 ASCO/CAP Clinical Practice Guidelines.
Mohanty SK; Mishra SK; Tiwari A; Sharma S; Bhardwaj M; Pattnaik N; Jaiswal S; Baisakh MR; Das S; Pradhan MR; Swain TR; Satpathy K; Williamson SR; Parwani AV
Am J Clin Pathol; 2021 Nov; 156(6):1130-1141. PubMed ID: 34124742
[TBL] [Abstract][Full Text] [Related]
9. Intense basolateral membrane staining indicates HER2 positivity in invasive micropapillary breast carcinoma.
Zhou S; Yang F; Bai Q; Li A; Li M; Zhong S; Lv H; Shui R; Tu X; Bi R; Xu X; Cheng Y; Yu B; Tang S; Sun X; Zhou X; Yang W
Mod Pathol; 2020 Jul; 33(7):1275-1286. PubMed ID: 31974492
[TBL] [Abstract][Full Text] [Related]
10. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.
Buza N; English DP; Santin AD; Hui P
Mod Pathol; 2013 Dec; 26(12):1605-12. PubMed ID: 23765245
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer.
Franceschini T; Capizzi E; Massari F; Schiavina R; Fiorentino M; Giunchi F
Pathol Res Pract; 2020 Aug; 216(8):153012. PubMed ID: 32703487
[TBL] [Abstract][Full Text] [Related]
12. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization.
Ching CB; Amin MB; Tubbs RR; Elson P; Platt E; Dreicer R; Fergany A; Hansel DE
Mod Pathol; 2011 Aug; 24(8):1111-9. PubMed ID: 21516078
[TBL] [Abstract][Full Text] [Related]
13. HER2 Equivocal (Score = 2+) Breast Carcinoma Cases Identified by Immunohistochemistry at a South African Hospital. What is the Impact of Fluorescent In Situ Hybridization Testing?
Mohanlal RD; Bouwer N; Willem P
Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):555-560. PubMed ID: 37471623
[TBL] [Abstract][Full Text] [Related]
14. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
Mentrikoski MJ; Stoler MH
Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
[TBL] [Abstract][Full Text] [Related]
15. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
Middleton LP; Price KM; Puig P; Heydon LJ; Tarco E; Sneige N; Barr K; Deavers MT
Arch Pathol Lab Med; 2009 May; 133(5):775-80. PubMed ID: 19415952
[TBL] [Abstract][Full Text] [Related]
16. Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry.
Taylor VJ; Barnes PJ; Godwin SC; Bethune GC
Virchows Arch; 2021 Jul; 479(1):23-31. PubMed ID: 33527151
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.
Isharwal S; Huang H; Nanjangud G; Audenet F; Chen YB; Gopalan A; Fine SW; Tickoo SK; Lee BH; Iyer G; Chadalavada K; Rosenberg JE; Bajorin DF; Herr HW; Donat SM; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
Hum Pathol; 2018 Jul; 77():63-69. PubMed ID: 29601842
[TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
O'Grady A; Allen D; Happerfield L; Johnson N; Provenzano E; Pinder SE; Tee L; Gu M; Kay EW
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):489-93. PubMed ID: 20661132
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer.
Farra C; Fedda F; Tfayli A; Tawil A; Zaatari G; Ashkar H; Issa G; Boulos F
Clin Breast Cancer; 2019 Oct; 19(5):340-344. PubMed ID: 31213407
[TBL] [Abstract][Full Text] [Related]
20. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
